Nevro Corp
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well a… Read more
Nevro Corp (NVRO) - Net Assets
Latest net assets as of December 2024: $231.01 Million USD
Based on the latest financial reports, Nevro Corp (NVRO) has net assets worth $231.01 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($553.84 Million) and total liabilities ($322.83 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $231.01 Million |
| % of Total Assets | 41.71% |
| Annual Growth Rate | 14.9% |
| 5-Year Change | -40.53% |
| 10-Year Change | -1.53% |
| Growth Volatility | 49.79 |
Nevro Corp - Net Assets Trend (2012–2024)
This chart illustrates how Nevro Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nevro Corp (2012–2024)
The table below shows the annual net assets of Nevro Corp from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $231.01 Million | -21.20% |
| 2023-12-31 | $293.14 Million | -9.49% |
| 2022-12-31 | $323.88 Million | +6.67% |
| 2021-12-31 | $303.62 Million | -21.84% |
| 2020-12-31 | $388.46 Million | +79.55% |
| 2019-12-31 | $216.35 Million | -11.87% |
| 2018-12-31 | $245.48 Million | -1.48% |
| 2017-12-31 | $249.17 Million | +0.06% |
| 2016-12-31 | $249.03 Million | +6.16% |
| 2015-12-31 | $234.59 Million | +36.34% |
| 2014-12-31 | $172.07 Million | +155.13% |
| 2013-12-31 | $67.44 Million | +54.64% |
| 2012-12-31 | $43.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nevro Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 74786600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $38.00K | 0.02% |
| Other Comprehensive Income | $-1.21 Million | -0.52% |
| Other Components | $1.05 Billion | 452.38% |
| Total Equity | $231.01 Million | 100.00% |
Nevro Corp Competitors by Market Cap
The table below lists competitors of Nevro Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Coremax Corp
TW:4739
|
$199.94 Million |
|
Seoul Food Ind Co Ltd
KO:004415
|
$199.96 Million |
|
Addnode Group AB Series B
LSE:0GMG
|
$200.01 Million |
|
Surya Semesta Internusa Tbk
JK:SSIA
|
$200.02 Million |
|
BingEx Ltd
NASDAQ:FLX
|
$199.88 Million |
|
Jiangnan Yifan Motor Co.Ltd
SHE:301023
|
$199.83 Million |
|
Zhejiang Aishida Electric Co Ltd
SHE:002403
|
$199.80 Million |
|
Soyea Technology Co Ltd
SHE:000909
|
$199.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nevro Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 293,145,000 to 231,008,000, a change of -62,137,000 (-21.2%).
- Net loss of 113,439,000 reduced equity.
- New share issuances of 3,546,000 increased equity.
- Other comprehensive income decreased equity by 969,000.
- Other factors increased equity by 48,725,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-113.44 Million | -49.11% |
| Share Issuances | $3.55 Million | +1.54% |
| Other Comprehensive Income | $-969.00K | -0.42% |
| Other Changes | $48.73 Million | +21.09% |
| Total Change | $- | -21.20% |
Book Value vs Market Value Analysis
This analysis compares Nevro Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.94x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.09x to 0.94x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $64.16 | $5.84 | x |
| 2013-12-31 | $99.22 | $5.84 | x |
| 2014-12-31 | $38.75 | $5.84 | x |
| 2015-12-31 | $8.83 | $5.84 | x |
| 2016-12-31 | $8.74 | $5.84 | x |
| 2017-12-31 | $8.47 | $5.84 | x |
| 2018-12-31 | $8.17 | $5.84 | x |
| 2019-12-31 | $7.02 | $5.84 | x |
| 2020-12-31 | $11.53 | $5.84 | x |
| 2021-12-31 | $8.72 | $5.84 | x |
| 2022-12-31 | $9.12 | $5.84 | x |
| 2023-12-31 | $8.15 | $5.84 | x |
| 2024-12-31 | $6.23 | $5.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nevro Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -49.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27.77%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 2.40x
- Recent ROE (-49.11%) is below the historical average (-28.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -43.49% | -104.50% | 0.37x | 1.13x | $-23.33 Million |
| 2013 | -38.57% | -110.70% | 0.31x | 1.12x | $-32.76 Million |
| 2014 | -17.83% | -94.19% | 0.16x | 1.18x | $-47.89 Million |
| 2015 | -28.74% | -96.88% | 0.24x | 1.24x | $-90.89 Million |
| 2016 | -12.76% | -13.91% | 0.53x | 1.73x | $-56.68 Million |
| 2017 | -14.71% | -11.22% | 0.72x | 1.82x | $-61.58 Million |
| 2018 | -20.04% | -12.70% | 0.84x | 1.89x | $-73.75 Million |
| 2019 | -47.92% | -26.57% | 0.83x | 2.17x | $-125.32 Million |
| 2020 | -21.38% | -22.94% | 0.46x | 2.03x | $-121.91 Million |
| 2021 | -43.27% | -33.95% | 0.67x | 1.89x | $-161.72 Million |
| 2022 | 0.93% | 0.74% | 0.67x | 1.86x | $-29.39 Million |
| 2023 | -31.46% | -21.69% | 0.67x | 2.17x | $-121.53 Million |
| 2024 | -49.11% | -27.77% | 0.74x | 2.40x | $-136.54 Million |
Industry Comparison
This section compares Nevro Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nevro Corp (NVRO) | $231.01 Million | -43.49% | 1.40x | $199.88 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |